Filana Therapeutics, Inc 8-K, filed Mar 17, 2023
Filana Therapeutics, Inc. (FLNA)
About this 8-K
Filana Therapeutics, Inc filed this 8-K on March 17, 2023, reporting on events of March 16, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
___________________
(Exact name of registrant as specified in its charter)
___________________
|
|
|
|
|
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
___________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|
|
ThereWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) | |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective on March 16, 2023, the Board of Directors of Cassava Sciences, Inc. (the “Board”) amended the Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan (the “Cash Incentive Plan”) to remove all of the Board’s non-employee directors (the “Non-employee Directors) as beneficiaries under the Cash Incentive Plan and the Non-employee Directors consented to such removal. The Non-employee Directors’ share of potential benefits under the Cash Incentive Plan were completely forfeited to Cassava Sciences, Inc. and will not be allocated to any other participant under the Cash Incentive Plan. The Non-employee Directors have not received, and as a result of such amendment will never receive, any payments under the Cash Incentive Plan.
Item 9.01. Financial Statements and Exhibits.
|
|
|
|
|
|
Exhibit Number |
| Description |
|
|
|
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
| CASSAVA SCIENCES, INC. |
| |
| a Delaware corporation |
| |
|
|
|
|
Date: March 16, 2023 |
|
|
|
| By: | /s/ ERIC J. SCHOEN |
|
|
| Eric J. Schoen |
|
|
| Chief Financial Officer |
|